[1] MEHTA SR, YUSUF S, PETERS RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study[J]. Lancet, 2001, 358(9281):527-533.
[2] QURESHI Z, HOBSON AR. Clopidogrel "resistance":where are we now[J]. Cardiovasc Ther, 2013, 31(1):3-11.
[3] HARMSZE A, VAN WERKUM JW, BOUMAN HJ, et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation[J]. Pharmacogenetics and Genomics, 2010, 20(1):18-25.
[4] JAN L. Application of oral antiplatelet therapy in the treatment of coronary heart disease[J]. Chinese Circulation Journal, 2012,27(4):317-318.
[5] ERLINGE D, JAMES S, DUVVURU S, et al. Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease[J]. Thromb Haemost, 2014, 111(5):943-950.
[6] MAO L, JIAN C, CHANGZHI L, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients:a meta-analysis based on 23,035 subjects[J]. Arch Cardiovasc Dis, 2013, 106(10):517-527.
[7] SCOTT SA, SANGKUHL K, GARDNER EE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19(CYP2C19) genotype and clopidogrel therapy[J]. Clinical Pharmacology & Therapeutics, 2011, 90(2):328-332.
[8] WIVIOTT SD, BRAUNWALD E, McCABE CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2007, 357(20):2001-2015.
[9] DOBESH PP, OESTREICH JH. Ticagrelor:pharmacokinetics, pharmacodynamics, clinical efficacy, and safety[J]. Pharmacotherapy, 2014, 34(10):1077-1090.
[10] XIONG R, LIU W, CHEN L, et al. A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes[J]. Int J Clin Exp Med, 2015, 8(8):13310-13316.
[11] CHEN S, ZHANG Y, WANG L, et al. Effects of dual-dose clopidogrel, clopidogrel combined with tongxinluo capsule, and ticagrelor on patients with coronary heart disease and CYP2C19*2 gene mutation after percutaneous coronary interventions (PCI)[J]. Med Sci Monit, 2017, 23:3824-3830.